jnm.snmjournals.org
Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our f...